Overview

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.46
Change (%) Stock is Up 0.02 (0.45%)
Volume8,912,385
Data as of 07/30/15 4:15 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
07/29/15MannKind Announces Stock and Note Exchange Agreements With Holders of Outstanding 5.75% Senior Convertible Notes
VALENCIA, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (the "Company" or "MannKind") (Nasdaq:MNKD) today announced that it has entered into separate, privately-negotiated exchange agreements with select holders of its existing 5.75% Senior Convertible Notes due 2015 (the "2015 notes") to exchange up to an aggregate principal amount of $84.6 million of the 2015 notes. Pursuant to the exchange agreements with certain holders (the "Note Exchange Agreements"), the Company has agree... 
Printer Friendly Version
06/09/15Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala
Mann, Early Developer of Pacemaker, Artificial Pancreas and Inhaled Insulin is Honored BOSTON, June 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy. Held in conjunction with the 75th annual American Diabetes Association Scientif... 
Printer Friendly Version
05/27/15MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.  Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, 2015 at 2:00 pm (ET) in New York, New York. Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, 2015 at 8:40 am (PT) at the Terranea Resort in Rancho Palos Verdes, ... 
Printer Friendly Version
05/21/15James S. Shannon Rejoins MannKind's Board of Directors
VALENCIA, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that James S. Shannon, MD, MRCP (UK) has been elected to the company's Board of Directors after previously serving as a director from February 2010 until April 2012. The addition of Dr. Shannon brings the total number of MannKind Board members to eight. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the positio... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet